Ms. Ouellet is just telling me that four years ago there were 45 investigations; now there are 90 investigations. So that means there are more drugs that seem to be offside in terms of the price. The rules haven't changed. We're hoping to modernize our guidelines, as we've mentioned before, in order to allow for a premium for these incremental innovations.
On February 12th, 2009. See this statement in context.